Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 5,156 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervical Clear all
Active, not recruiting Phase 2 Interventional

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

NCT02713269
View directory record Official record
Conditions
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Melanoma, Prostate Carcinoma Metastatic in the Bone, Sarcoma, Solid Neoplasm, Spinal Cord Compression, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Thyroid Gland Carcinoma
Interventions
Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Thermal Ablation Therapy
Procedure · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 25, 2026, 2:19 AM EDT
Recruiting Phase 2 Interventional

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

NCT05541016
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Diffusing Alpha-emitter Radiation Therapy, Docetaxel, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Modified Barium Swallow Study, Observation Activity, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire
Procedure · Drug · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 2:19 AM EDT
Withdrawn Not applicable Interventional

Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients

NCT05099952
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Biospecimen Collection, Counseling, Educational Intervention, Electronic Health Record Review, Medical Device Usage and Evaluation, Questionnaire Administration
Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Phase 1 Interventional

A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

NCT04752215
View directory record Official record
Conditions
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
Interventions
BI 765049, ezabenlimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Not applicable Interventional

CPR Decision Aid For Patients With Advanced Gynecologic Malignancies

NCT03251976
View directory record Official record
Conditions
Advance Care Planning
Interventions
video, usual care
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 25, 2026, 2:19 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

NCT03693014
View directory record Official record
Conditions
Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
Interventions
Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
Radiation · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
10
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Phase 2 Interventional

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer

NCT00201747
View directory record Official record
Conditions
Esophageal Cancer, Esophagus Cancer, Cancer of Stomach, Stomach Cancer
Interventions
CPT-11, Mitomycin C
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 25, 2026, 2:19 AM EDT
Recruiting Phase 2 Interventional

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

NCT06980038
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasal Cavity Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasal Cavity Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8
Interventions
Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection, Cemiplimab, Computed Tomography, Positron Emission Tomography, Tumor Resection
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
Irvine, California • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Not applicable Interventional Results available

Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients

NCT03351335
View directory record Official record
Conditions
Mild to Moderate Skin Laxity Under the Chin, Mild to Moderate Skin Laxity on Neck
Interventions
Microfocused ultrasound with visualization
Device
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
35 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Los Gatos, California • San Diego, California • Vista, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 25, 2026, 2:19 AM EDT
Active, not recruiting Phase 1 Interventional

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
Livmoniplimab, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Not applicable Interventional

Temporal Variation in Exhaled Volatile Organic Compounds in Esophageal Cancer Patients

NCT06453993
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Exhaled VOC breath test
Other
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 25, 2026, 2:19 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma

NCT07428148
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma
Interventions
Induction Chemo-Immunotherapy, Lattice Radiotherapy
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 25, 2026, 2:19 AM EDT
Terminated Phase 4 Interventional Results available

Nutrition and Pharmacological Algorithm for Oncology Patients Study

NCT04155008
View directory record Official record
Conditions
Oncologic Complications, Quality of Life, Nutrition Poor, Head and Neck Cancer, Lung Cancer, Pancreatic Cancer
Interventions
Dexamethasone, Dronabinol, Mirtazapine, Nutrition Intervention
Drug · Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Phase 1 Interventional

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

NCT00019825
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
Interventions
decitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Not applicable Interventional

Aromatherapy to Reduce Pain and Anxiety During Cervical Colposcopy

NCT01214304
View directory record Official record
Conditions
Colposcopy
Interventions
Essential Lavender Oil, Lavender Scent
Other
Lead sponsor
Mike O'Callaghan Military Hospital
Federal
Eligibility
18 Years and older · Female only
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 25, 2026, 2:19 AM EDT
Withdrawn Phase 3 Interventional

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

NCT03386838
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Nivolumab, BMS-986205, Cetuximab, Cisplatin, Carboplatin, Fluorouracil
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 25, 2026, 2:19 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer

NCT06234748
View directory record Official record
Conditions
Oropharynx Cancer, HPV-Related Carcinoma
Interventions
Radiation, Platinum based chemotherapy
Radiation · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 25, 2026, 2:19 AM EDT
Terminated Phase 1 Interventional

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

NCT06336148
View directory record Official record
Conditions
Solid Tumor
Interventions
ACTM-838
Drug
Lead sponsor
Actym Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Phase 1 Interventional

Anti-OX40 Antibody in Head and Neck Cancer Patients

NCT02274155
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Anti-OX40 antibody administration, Surgical Resection
Drug · Procedure
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 25, 2026, 2:19 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

NCT05572684
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
Interventions
NC410, pembrolizumab
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Phase 1 Interventional

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

NCT04670679
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
ERAS-601, Cetuximab, Pembrolizumab
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Sarasota, Florida • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 25, 2026, 2:19 AM EDT
Active, not recruiting Phase 2 Interventional

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

NCT05913388
View directory record Official record
Conditions
Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
Interventions
GB1211, Pembrolizumab, Placebo
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 2:19 AM EDT
Completed No phase listed Observational

Evaluation of Robot-Assisted Surgery in Gynecologic Oncology

NCT00671827
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
2
States / cities
Gilbert, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Platelet-Rich Fibrin in the Healing of Regional and Free Flaps

NCT04023474
View directory record Official record
Conditions
Head and Neck Disorder, Free Flap
Interventions
Platelet Rich Fibrin (PRF) Application
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 25, 2026, 2:19 AM EDT